Biogen is discontinuing development of an experimental therapy for a rare brain disease after the treatment failed a mid-stage trial, the latest setback in attempts to develop a medicine for the disorder.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2019-12-13 08:33:312019-12-13 08:33:31Biogen scraps development of therapy for rare brain disease
